Contribute Try STAT+ Today

Two years ago, a manufacturing team leader at AbbVie (ABBV) took a similar job at an aspiring rival that planned to make a biosimilar version of Humira, its best-selling product. But before leaving, the employee allegedly transferred a raft of confidential information about the steps needed to produce the blockbuster medicine, according to a lawsuit filed by AbbVie in a federal court.

In its lawsuit, AbbVie contended that a company based in Iceland known as Alvotech recruited Rongzan Ho in its quest to jumpstart its entry into the market for biosimilar versions of Humira. The biologic treatment is widely prescribed to combat rheumatoid arthritis, among other ailments, and racked up nearly $20 billion in worldwide sales that year, including $13.7 billion in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.